Qiagen N.V. logo

Qiagen N.V.

QGEN | NYSE
Chart Builder DCF Calculator
$50.37
+$0.15 (+0.30%)
Nov 2, 2026, 12:14 PM ET · Market open

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Key Executives

Name Position
Jonathan Pratt CEO & Member of Management Board
Roland Sackers Chief Financial Officer, MD & Member of Management Board
Antonio Santos Senior Vice President & Head of Global Operations
Daniel Wendorff CEFA CIIA VP & Head of Investor Relations
Jean-Pascal Viola Senior Vice President & Head of Corporate Strategy and Business Development
John Gilardi Vice President & Head of Corporate Communications
Michael Scheffler Vice President & Head of Global Sample Technologies
Nitin Sood Senior VP & Head of Product Portfolio & Innovation
Stephany Foster Senior Vice President & Head of Human Resources
Thierry Bernard Member of Management Board
Thomas Schweins Senior Vice President of Life Science Business Area
Thomas Theuringer Senior Director & Head of External Communications

Latest SEC Filings

Date Type Title
Sep 09, 2026 6-K Filing
Aug 07, 2026 6-K Filing
Aug 07, 2026 6-K Filing
Aug 07, 2026 6-K Filing
Jun 05, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 01, 2026 SD Filing
May 08, 2026 6-K Filing
May 08, 2026 6-K Filing
Mar 20, 2026 IRANNOTICE Filing
Mar 20, 2026 20-F Filing
View All SEC Filings ➞
Qiagen N.V.
Qiagen N.V. logo
Country Netherlands
IPO Date Jun 28, 1996
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 5,500
CEO Jon Pratt

Contact Details

Hulsterweg 82 Venlo, LI 5912 PL Netherlands

Stock Details

Ticker Symbol QGEN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001015820
CUSIP Number n/a
ISIN Number NL0015002SN0
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.